First versus second eye intravitreal ranibizumab therapy for wet AMD

Retina

Volumn 29, Issue 3, 2009, Pages 325-328

  Eldaly, Mohamed A ^a,c   Styles, Caroline ^b  

^a CAIRO UNIVERSITY   (Egypt)

^b QUEEN MARGARET HOSPITAL   (United Kingdom)

^c NONE   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

RANIBIZUMAB;

AGED; ARTICLE; CONTRAST SENSITIVITY; CONTROLLED STUDY; ENDOPHTHALMITIS; EYE; FEMALE; HUMAN; INTRAOCULAR PRESSURE ABNORMALITY; MAJOR CLINICAL STUDY; MALE; RETINA DETACHMENT; RETINA MACULA AGE RELATED DEGENERATION; STROKE; TREATMENT OUTCOME; VISION; VISUAL ACUITY; VISUAL IMPAIRMENT; VITREOUS HEMORRHAGE;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS; MACULAR DEGENERATION; MALE; RETINA; TIME FACTORS; TREATMENT OUTCOME; VISION TESTS; VISUAL ACUITY; VITREOUS BODY;

EID: 67749124168     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IAE.0b013e31819a6154     Document Type: Article

References (10)

1. Ardourel JE. Risk factors associated with age-related macular degeneration: a case-control study in the Age-Related Eye Disease Study: Age-Related Eye Disease Study report number 3. Ophthalmology 2000;107:2224 -2232.
2. Gross NE, Aizman A, Brucker A, Klancnik JM Jr, Yannuzzi LA. Nature and risk of neovascularization in the fellow eye of patients with unilateral retinal angiomatous proliferation. Retina 2005;25:713-718.
3. Gaudreault J, Fei D, Beyer JC, et al. Pharmacokinetics and retinal distribution of ranibizumab, a humanized antibody fragment directed against VEGF-A, following intravitreal administration in rabbits. Retina 2007;27:1260-1266.
4. Rosenfeld PJ, Brown DM, Heier JS, et al; for the MARINA Study Group. Ranibizumab for neovascular age-related mac-ular degeneration. N Engl J Med 2006;355:1419-1431.
5. Brown DM, Kaiser PK, Michels M, et al; ANCHOR Study Group. Subgroup analysis ranibizumab vrs verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-1444.
6. Regillo CD, Brown DM, Abraham P, et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study Year 1. Am J Ophthalmol 2008;145:239-248.
7. Bansback N, Davis S, Brazier J. Using contrast sensitivity to estimate the cost-effectiveness of verteporfin in patients with predominantly classic age-related macular degeneration. Eye 2007;21:1455-1463.
8. Moutray T, Alarbi M, Mahon G, Stevenson M, Chakravarthy U. Relationships between clinical measures of visual function, fluorescein angiographic and optical coherence tomography features in patients with subfoveal choroidal neovascularisation. Br J Ophthalmol 2008;92:361-364.
9. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805-2816.
10. Steinbrook R. The price of sight-ranibizumab, bevacizumab, and the treatment of macular degeneration. N Engl J Med 2006;355:1409-1412.